Latest

Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine

Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine

Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.

RA Risk Increased With Occupational Exposure to Noxious Fumes

RA Risk Increased With Occupational Exposure to Noxious Fumes

Cases and controls were examined to determine the relationship between occupational exposure to noxious fumes and rheumatoid arthritis.

Sign Up for Free e-newsletters